MapLight officer proposes $1.68M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MapLight Therapeutics, Inc. (MPLT) officer Erin Pennock Foff reported a proposed sale of 54,718 common shares, with an aggregate market value of $1,679,842.60 and an approximate sale date of May 4, 2026. The shares were acquired through vested restricted stock units. The notice states sales are to be made pursuant to a previously signed/adopted Rule 10b5-1 selling plan dated December 29, 2025. Recent sales listed were 2,044 shares on April 15 and 1,169 shares on April 16, 2026.
Key Figures
Key Terms
Aggregate Market Value financial
Vested RSU financial
10b5-1 Selling plan regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Was Erin Pennock Foff's proposed MPLT sale under a 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.